Acquisition Announced

Biogen acquisition of Apellis Pharmaceuticals

US$5.6bn equity value

Announced 31 Mar 2026 · US$41.00 cash and scrip per share

Advisers

Apellis Pharmaceuticals

Target

Financial adviser

Biogen

Acquirer

Financial adviser
Legal adviser

Other advisers

Financial adviser
Target
Apellis Pharmaceuticals
Acquirer
Biogen
Target based in
United States
Buyer based in
United States
Sector
Biotech
Tags
Biotech, Pharma, Ophthalmology

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.